Oxidative Stress Does Not Influence Subjective Pain Sensation in Inflammatory Bowel Disease Patients

Abstract

Oxidative stress (OS) has been proposed as a significant causative and propagating factor in inflammatory bowel diseases (IBDs). Modulation of OS is possible through antioxidants and inhibition of oxidizing enzymes. Thirty-one IBD patients and thirty-two controls were included in the study. The aim was to examine the levels of OS in colonic tissue of IBD requiring surgical intervention and control group, and their association with pain intensity. Total antioxidant capacity (TAC), superoxide dismutase (SOD) and catalase (CAT) activity, glutathione (GSH) and oxidized glutathione (GSSG) levels, and glutathione peroxidase (GPX) activity as markers of antioxidant defense were determined. Cyclooxygenases activities (Total COX, COX-1 and COX-2) were measured as prooxidant enzymes. Thiobarbituric acid reactive substances (TBARS) concentrations were measured to evaluate lipid peroxidation. Disease activity was assessed, and each subject filled out VAS and Laitinen’s pain assessment scales. Correlation between the OS, pain intensity, disease activity parameters, C-reactive protein (CRP), number of stools passed daily, disease duration, and dietary habits was investigated. No TAC differences were found between the groups. A significant decrease of SOD activity and GSH and GSSG levels was seen in IBD patients vs. controls, while GPX activity was diminished significantly only in CD patients. CAT and COX-1 activity was increased, and COX-2 significantly decreased in IBD. TBARS were significantly higher in CD patients compared to control group. No correlation was found between pain scores, inflammatory status, disease activity, disease duration, or dietary habits and OS markers. In our study, OS did not influence pain sensation reported by IBD patients.

CAPE Improves Vanin-1/AKT/miRNA-203 Signaling Pathways in DSS-induced Ulcerative Colitis

“…In the present study, we noticed depletion of colon GSH, GPx, CAT, and SOD in DSS-treated rats. Our results were in line with the results reported by Zieliska et al 66 , who observed a significant decrease in GSH, GPx, CAT, and SOD levels in patients with IBD when compared with controls. Our results indicate that the administration of CAPE significantly improves macroscopic damage, colon length, increases the activity of GPx, CAT, and SOD, depresses TBARs and NO levels, and increases GSH levels in the colon tissues of experimental colitis.…”

Sirtuin 3 ameliorates inflammatory bowel disease via inhibiting intestinal inflammation and oxidative stress

“…( 20 ) In IBD patients, a significant decrease of SOD activity and GSH level was seen. ( 21 ) Sirt3 has been demonstrated to regulate oxidative stress by modulating key antioxidants. Mechanistically, Sirt3 directly deacetylates the MnSOD 122-lysine residue in the mitochondria, enhancing its ability to neutralize ROS.…”

Network pharmacology and molecular docking reveal zedoary turmeric-trisomes in Inflammatory bowel disease with intestinal fibrosis

“…Formononetin, as an active component of flavonoids extracted naturally, was recently applied in a variety of disease models as a new inflammatory inhibitor and may have potential therapeutic value for IBD by activating Nrf2 expression[ 21 ]. Zielińska et al [ 22 ] showed that stigmasterol significantly reduced the inflammatory factors IL-1β, IL-6, and MCP-1 and the related cytokine synthase COX-2, inhibited colon shortening, and reduced the severity of IBD. These researchers also found that stigmasterol had greater anti-inflammatory activity than β-sitosterol and inhibited the symptoms of colitis[ 23 ].…”